Accordingly, we hypothesized that asynchronous increases in serum iFGF23 and cFGF23 levels in advanced CKD patients may lead to different forms of FGF23 with varying predictive power for clinical outcomes in dialysis patients. This evidence concerns the gene FGF23 and chronic kidney disease.